Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to see if the participant's genetic profile and clinical factors (age, drug dose, etc.) affect drug outcomes (i.e. serious bleeding) that the participant may have experienced since taking the drug (direct oral anticoagulant) for preventing blood clots from forming in the blood vessels.


Clinical Trial Description

Genes can have variants or mutations that can increase the participant's risk for bleeding when receiving a direct oral anticoagulant (DOACs). The investigators will be studying participants on DOACs who have had bleeding and also participants who are on DOACs who did not have bleeding (control group). The goal of the study is to determine the accuracy of Cipherome's Drug Safety Score (DSS) in it's ability to predict adverse drug reactions (ADRs). A DSS score ranges from 0 to 1, with scores less than 0.3 correlated with a higher risk of ADRs and scores more than 0.7 correlated with a lower risk of ADRs. The participant's DSS score will be compared with the actual clinical outcome using a statistical test to determine the accuracy of the DSS. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04580589
Study type Observational
Source Cipherome, Inc.
Contact
Status Completed
Phase
Start date February 1, 2021
Completion date October 31, 2022

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03258151 - Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
Recruiting NCT05202964 - Compliance and Tolerance to Oral AntiBiotherapy in Osteoarticular Infections (OTABIO)
Completed NCT04597593 - Association Between Genetic Variant Scores and DOACs (DARES2)
Recruiting NCT05096338 - Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Prostate Cancer
Recruiting NCT05078190 - Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast Cancer
Completed NCT02457039 - Acupuncture Prevents Chemobrain in Breast Cancer Patients N/A
Completed NCT02779530 - CYP4A11 and CYP4F2 Gene Variants as Makers of Cardiovascular Adverse Events of Non-steroidal Anti-inflammatory Drugs Phase 4
Recruiting NCT03051880 - Preventive Effect of EGF Cream for Cutaneous Adverse Event of EGFR Inhibitors N/A
Recruiting NCT03047863 - Therapeutic Effect of EGF Cream for Cutaneous Adverse Event of EGFR Inhibitors N/A
Completed NCT02482025 - The Secure Messaging for Medication Reconciliation Tool (SMMRT) Trial N/A
Not yet recruiting NCT03147157 - The Effect of Human Leukocyte Antigen Macthing on Guiding Tacrolimus Regimen After Liver Transplantation N/A
Recruiting NCT03156348 - Impact of Clinical Pharmacist on Adverse Drug Events in Older Adults N/A
Recruiting NCT03501108 - Discontinuation of Long-term Medications in Older People Entering Nursing Home Care N/A
Recruiting NCT06427317 - Routinely Collected Clinical Data and Evaluation of Antimicrobial Target Attainment
Completed NCT03227653 - Neuropsychiatric Side Effects of Efavirenz in Children Living With HIV
Completed NCT03177174 - Different Chemotherapy Protocols Combined With Intensity Modulated Radiation Therapy in Patients With Locally Advanced Nasopharyngeal Carcinoma N/A
Recruiting NCT04077281 - Improving Medication Prescribing-Related Outcomes for Vulnerable Elderly In Transitions N/A
Not yet recruiting NCT05247814 - Individual Risk Profiles for Adverse Drug Reactions in Geriatric Patients
Recruiting NCT03938597 - Investigation of Serious Adverse Events Following Vaccination Against Yellow Fever: Emphasis on Genetic Basis and Biological Markers
Recruiting NCT06291688 - Applying Mobile Healthcare Education to Improve Cutaneous Self-care Capability N/A